National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
In English | En español
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 2/9/2009     First Published: 12/23/2003  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?
Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Genetic Study of Mutations in Participants Previously Enrolled in NCI-99-C-0053 Who Have von Hippel-Lindau (VHL) Syndrome or Who Are at Risk for VHL Syndrome

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedGeneticsCompletedAdultNCINCI-03-C-0148
NCT00075348

Objectives

  1. Obtain laboratory identification and confirmation of research results for gene mutations in participants previously enrolled in NCI-99-C-0053 who have von Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome.
  2. Determine genotype status in these participants.

Entry Criteria

Disease Characteristics:

  • Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study NCI-99-C-0053


  • Meets 1 of the following criteria:
    • Diagnosis of VHL syndrome
    • At risk of VHL syndrome
    • Family member of patient with VHL syndrome


  • VHL syndrome genotype is not known


Prior/Concurrent Therapy:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Patient Characteristics:

Age

  • Adult

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Expected Enrollment

260

A maximum of 260 participants will be accrued for this study.

Outline

Participants submit a blood or buccal sample for genetic mutation analysis. Participants may receive genetic counseling and/or the results of genetic testing, if desired.

Trial Contact Information

Trial Lead Organizations

NCI - Center for Cancer Research

William Linehan, MD, Protocol chair
Ph: 301-496-6353

Related Information

PDQ® clinical trial NCI-99-C-0053

Registry Information
Official Title Genetic Mutation Analysis In A VHL Population
Trial Start Date 2003-12-31
Trial Completion Date 2008-12-23
Registered in ClinicalTrials.gov NCT00075348
Date Submitted to PDQ 2003-04-11
Information Last Verified 2008-11-30

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov